Homocysteine activates platelets in vitro

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 1, 2008, Pages 8-18

  Mohan, Irwin V ^a,b   Jagroop, I Anita ^c   Mikhailidis, Dimitri P ^c   Stansby, Gerard P ^a,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WESTMEAD HOSPITAL   (Australia)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Aggregation; Homocysteine; Platelet; Platelet shape change; Thromboelastography

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR; HOMOCYSTEINE; HYPOCHOLESTEROLEMIC AGENT; LACTATE DEHYDROGENASE; NITRATE; PADGEM PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DIABETES MELLITUS; ERYTHROCYTE MEMBRANE; FEMALE; FLOW CYTOMETRY; HUMAN; HYPERTENSION; IN VITRO STUDY; ISCHEMIC HEART DISEASE; LIMB ISCHEMIA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE SHAPE; THROMBOELASTOGRAPHY;

CASE-CONTROL STUDIES; EXTREMITIES; FEMALE; HOMOCYSTINE; HUMANS; ISCHEMIA; MALE; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOPHILIA; THROMBOSIS;

EID: 37549032787     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607308390     Document Type: Article

References (51)

1. Kang SS, Wong PWK, Malinow MR Hyperhomocyst(e)-inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992 ; 12: 279-298.
2. Boers GH, Smals AG, Trijbels JM, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985 ; 313: 709-715.
3. Cacciari E., Salardi S. Clinical and laboratory features of homocystinuria. Haemostasis. 1989 ; 19 (Suppl 1). 10-13.
4. Den Heijer M., Koster T., Blom HJ, et al. Hyperhomocysteinaemia as a risk factor for deep vein thrombosis. N Engl J Med. 1996 ; 334: 759-762.
5. Den Heijer M., Lewington S., Clarke R. HCY, MTHFR, and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005 ; 3: 292-299.
6. McDonald L., Bray C., Field C., Love F., Davies B. Homocysteinuria, thrombosis, and the blood-platelets. Lancet. 1964 ; 1: 745-746.
7. Harker LA, Slichter SJ, Scott CR, Ross R. Hyperhomocysteinaemia, vascular injury and arterial thrombosis. N Engl J Med. 1974 ; 291: 537-543.
8. Uhlemann ER, TenPas JH, Lucky AW, Schulman JD, Mudd SH, Shulman NR. Platelet survival and morphology in homocysteinuria due to cystathione synthetase deficiency. N Engl J Med. 1976 ; 295: 1283-1286.
9. Hilden M., Brandt NJ, Nilsson IM, Schonheyder F. Investigation of coagulation ad fibrinolysis in homocysteinuria. Acta Med Scand. 1974 ; 195: 533-535.
10. Harker LA, Scott CR Platelets in homocysteinuria. N Engl J Med. 1977 ; 296: 818.
11. Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart M. Effect of HCY and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res. 1982 ; 16: 490-493.
12. Patrono C., Ciabattoni G., Davi G. Thromboxane-dependent platelet activation as a transducer of enhanced risk of coronary and cerebral thrombosis. Adv Prostaglandin Thromboxane Leukot Res. 1991 ; 21B: 619-622.
13. Roberts LJ, Sweetman BJ, Oates JA Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem. 1981 ; 256: 8384-8393.
14. Di Minno G., Davi G., Margaglione M., et al. Abnormally high thromboxane biosynthesis in homozygous homocysteinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest. 1993 ; 92: 1400-1406.
15. Signorello MG, Pascale R., Leoncini G. Effects of HCY on arachidonic acid release in human platelets. Eur J Clin Invest. 2002 ; 32: 279-284.
16. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res. 2001 ; 88: 756-762.
17. Mikhailidis DP, Barradas MA, Mier A., et al. Platelet function in patients admitted with a diagnosis of myocardial infarction. Angiology. 1987 ; 38: 36-45.
18. Mikhailidis DP, Hutton RA, Jeremy JY, Dandona P. Cooling decreases the efficiency of prostaglandin inhibitors of platelet aggregation. Microcirculation. 1983 ; 2: 413-423.
19. Barradas MA, O'Donoghue S., Jagroop A., Mikhailidis DP Laboratory techniques in drug development (2): advantages of whole blood platelet aggregation measured by a cell counter (Coulter T-890) in drug evaluation. J Drug Dev. 1992 ; 5: 155-166.
20. Frojmovic MM Comparative studies of turbidimetrically measured rates of platelet aggregation require adjustment of the platelet suspension according to the mean relative size and optical efficiency of the platelets used. Blood. 1989 ; 74: 2302-2303.
21. Lumley P., Humphrey PP A method for quantitating platelet aggregation and analyzing drug-receptor interactions on platelets in whole blood in vitro. J Pharmacol Methods. 1981 ; 6: 153-166.
22. Armstrong R., May J., Losche W., Heptinstall S., Mitchell J. Factors that contribute to spontaneous platelet aggregation and streptokinase induced aggregation in whole blood. Thromb Haemost. 1995 ; 73: 297-303.
23. Shattil SJ, Cunningham M., Hoaxie JA Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood. 1987 ; 70: 307-315.
24. Hartert H. The physical and biological constants of thromboelastography. Biorheology. 1962 ; 1: 31-39.
25. Mikhailidis DP, Barradas MA, O'Donoghue S., Dandona P. Evidence for in vivo platelet activation following the injection of conventional unfractionated heparin. Platelets. 1990 ; 1: 189-192.
26. Barradas MA, O'Donoghue S., Mikhailidis DP Measurement of platelet volume using a channelyzer: assessment of the effect of agonists and antagonists. in vivo. 1992 ;6: 629-634.
27. Michelson AD, Barnard MR, Hechtmann HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A. 1996 ; 93: 11877-11882.
28. Riba R., Nicolaou A., Troxler M., Homer-Vaniasinkam S., Naseem KM Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis. 2004 ; 175: 69-75.
29. Audier M. A Serradimigni: Savoir interpreter un thrombo-elastogramme ou l'exploration precise de la coagulation sanguine. Paris, France: Maloine ; 1962.
30. Raby C, ed. Exploracion del tiempo trombodinamico: In Hemorragias y Trombosis. Barcelona, Spain: Toray- Masson ; 1968.
31. Andersson A., Lindgren A., Hultberg B. Effect of thiol oxidation and thiol export from erythrocytes on determination of redox status of homocysteine and other thiols in plasma from healthy subjects and patients with cerebral infarction. Clin Chem. 1995 ; 41: 361-366.
32. Velury S., Howell SB Measurement of plasma thiols after derivatization with monobromobimane. J Chromatogr. 1988 ; 424: 141-146.
33. Misra HP Generation of superoxide free radical during the autoxidation of thiols. J Biol Chem. 1974 ; 249: 2151-2155.
34. Rowley DA, Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of thiol compounds. FEBS Lett. 1982 ; 138: 33-36.
35. Loscalzo J. The oxidant stress of hyperhomocysteinaemia. J Clin Invest. 1996 ; 98: 5-7.
36. Heinecke JS Superoxide mediated oxidation of low-density lipoproteins by thiols. In: Cerruti PA, Cerruti JM, McCord I, Fridovich, eds. Oxy-radicals in Molecular Biology and Pathology. New York, NY: Alan R Liss ; 1988: 433-457.
37. Ardlie NG, Selley ML, Simons LA Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis. 1989 ; 76: 117-124.
38. Parthasarathy S., Fong LG, Otero D., Steinberg D. Recognition of solubilised apoproteins from delipidated, oxidised low density lipoprotein (LDL) by the acetyl-LDL receptor. Proc Natl Acad Sci U S A. 1987 ; 84: 537-540.
39. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A. 1992 ; 89: 10193-10197.
40. Coppola A., Davi G., De Stefano V., Mancini FP, Cerbone AM, Di Minno G. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost. 2000 ; 26: 243-254.
41. Palaretti G., Salardi S., Piazzi S., et al. Blood coagulation changes in homocysteinuria: effects of pyridoxine and other specific therapy. J Pediatr. 1986 ; 109: 1001-1006.
42. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR Vascular dysfunction in monkeys with diet-induced hyperhomocysteinaemia. J Clin Invest. 1996 ; 98: 24-29.
43. Ueland PM, Refsum H., Stabler SP, Malinow MR, Andersson A., Allen RH Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem. 1993 ; 39: 1764-1779.
44. Upchurch GR, Welch GN, Loscalzo J. HCY, ERDF and endothelial function. J Nutr. 1996 ; 126: 1290S - 1294S.
45. McDonald LJ, Murad F. Nitric oxide and cyclic GMP signaling. Proc Soc Exp Biol Med. 1996 ; 211: 1-6.
46. Upchurch GR, Welch GN, Fabian AJ, Pigazzi A., Keaney JF, Loscalzo J. Stimulation of endothelial nitric oxide production by homocyst(e)ine. Atherosclerosis. 1997 ; 132: 177-185.
47. Ignarro LJ, Gruetta CA Requirement of thiols for activation of coronary arterial guanylate cyclase by glyceryl trinitrate and sodium nitrite: possible involvement of S-nitrosothiols. Biochem Biophys Acta. 1980 ; 631: 221-231.
48. Stampfer JS, Osborne JA, Jakari O., et al. Adverse effects of HCY are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993 ; 91: 308-318.
49. Starkebaum G., Harlan JM Endothelial cell injury due to copper-catalysed hydrogen peroxide generation from HCY. J Clin Invest. 1986 ; 77: 1370-1376.
50. Jia L., Furchgott RF Inhibition of sulfhydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor. J Pharmacol Exp Ther. 1993 ; 267: 371-378.
51. Upchurch GR, Welch GN, Ramdev N., Fabian AJ, Keaney JF, Loscalzo J. The effect of homocysteine on endothelial cells nitric oxide production. FASEB J. 1995 ; 9: A876.